WO1991018669A1 - Procede servant a preparer des microemulsions - Google Patents

Procede servant a preparer des microemulsions Download PDF

Info

Publication number
WO1991018669A1
WO1991018669A1 PCT/US1991/003991 US9103991W WO9118669A1 WO 1991018669 A1 WO1991018669 A1 WO 1991018669A1 US 9103991 W US9103991 W US 9103991W WO 9118669 A1 WO9118669 A1 WO 9118669A1
Authority
WO
WIPO (PCT)
Prior art keywords
oil
emulsion
surfactant
microemulsion
process according
Prior art date
Application number
PCT/US1991/003991
Other languages
English (en)
Inventor
Seang H. Yiv
Original Assignee
Affinity Biotech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affinity Biotech, Inc. filed Critical Affinity Biotech, Inc.
Priority to JP3514039A priority Critical patent/JPH06511419A/ja
Publication of WO1991018669A1 publication Critical patent/WO1991018669A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers

Definitions

  • This invention relates to the preparation of microemulsions for pharmaceutical applications in which an oil such as a triglyceride is dispersed in an aqueous phase with the aid of eiulsifiers.
  • the emulsions are useful as drug carriers.
  • Microemulsions display indicia of inherent stability and behave as solutions, i.e., as a single phase. They are well known in the enhanced oil recovery art and have achieved some recognition in medical applications. See, e.g., U.S. 3,989,843 to Pierre Chabert et al. Su-jh emulsions can be formed with relatively mild agitation and are stable for months over a specified temperature range. Ideally, the range of temperature stability encompasses the intended use which, for internal medical application, is about 18-43°C, i.e., from slightly below room temperature to the temperature of a high fever.
  • microemulsion designating a very small particle size. While this is in accord with the general definition of the term micro, more recently, microemulsion has come to refer to emulsions whose ease of preparation indicates an inherent stability and whose long-term stability goes well beyond that displayed by ordinary emulsions, even those of very small particle size. Along these lines, it will usually be found that where the micro descriptor refers merely to particle size, the emulsion is made with homogenizers, fluidizers or other high shear procedures which are characteristically unnecessary with "true” microemulsions. See, for example, European Patent Application 0211258.
  • microemulsions are well known. Their indefinite shelf life adds to the useful life of the product and the small particle size allows them to reach parts of the body larger particles would not. This latter aspect is particularly important when an emulsion is used to carry drugs, as opposed to, say, nutrients, since localized delivery of the drug is often essential to receiving its optimum therapeutic value.
  • My invention is an improved process for forming a microemulsion which involves heating a coarse emulsion of the ingredients at above a critical temperature, the phase inversion temperature (PIT) , to "break" this coarse emulsion into two phases and then cooling to below the PIT with gentle mixing until the microemulsion forms.
  • PIT phase inversion temperature
  • This passage through the PIT results in a smaller particle size emulsion of greater stability than is obtained by conventional mixing methods.
  • My emulsions not only have a very small particle size but they are dilutable, without breaking, with water and normal biological fluids. It is also important that my composition contain one high molecular weight surfactant having a molecular weight greater than 2000 and that it be dissolved in the oil when the coarse emulsion is formed.
  • the oil is usually a fatty oil such as a fatty acid ester, preferably a di or triester of glycerol or propylene glycol. They are well-known under such names as soy bean oil, lard oil, safflower oil, olive oil, coconut oil, Captex, etc. Preferably, it is a saturated vegetable oil. For the present purpose, it should be a C 8 -C 20 , i.e., each fatty acid chain has 8-20 carbon atoms, more preferably C 8 -C 15 . Mineral oils such as pharmaceutical or food grade white oils are also suitable and the oil can be natural or synthetic.
  • the amount of the fatty oil is 1-40 percent, preferably 1-20%, more preferably 2-10%. All percentages herein are volume percent, indicated as merely %, or are weight volume percent; indicated as w/v %, which is_ the grams per 100 ml. of emulsion. More fatty oil generally requires more emulsifier.
  • the aqueous phase will often contain osmotic agents such as sodium chloride and/or glycerol to maintain the osmolarity at about 300 milliosmols, the osmolarity of human blood.
  • osmotic agents such as sodium chloride and/or glycerol to maintain the osmolarity at about 300 milliosmols, the osmolarity of human blood.
  • the use of such an agent will often depend on how much emulsion is to be injected. If being used as a drug carrier, then for some drugs, only a milliliter or so of emulsion may be necessary. This amount is small enough, compared to the total human " Blood volume, that no adverse effect on osmolarity may occur without an osmolarity agent being included in the emulsion.
  • the emulsifier used in my invention is nonionic and can be a single surfactant or a combination. At least one component of the surfactant should have a molecular weight above 2000, preferably above 2500, more preferably above 3000. As is well known the surfactant will be selected to provide an HLB to match that of the oil, the HLB being a well-known value which indicates the hydrophilicity of an emulsifier or emulsifier combination. Usually the HLB will be 10-15, preferably 11-13. As the subsequent examples show, this can often be achieved with a single surfactant. Suitable surfactants are polyoxyethylene fatty acid tri or higher esters of glycerol or sorbitol (or sorbitan) .
  • the fatty acid is C 8 -C 30 , preferably C 10 -C 20 , more preferably C 12 -C 18 .
  • Typical materials available commercially are Emulphor, Cremophor, Tween, Cirrasol and the like.
  • a second emulsifier component is sometimes helpful such as a fatty acid mono or diesters of glycerol or sorbitol (or sorbitan) such as Spans which may as well contain polyoxyethylene groups, the fatty acid and polyoxyethylene being as described above.
  • the amount of surfactant will generally be 2-40%, preferably 2-30%, more preferably 5-20%.
  • the surfactant:oil ratio is from .2:1 to 2:1.
  • My emulsions usually have average particle size of 10-80 nanometers, preferably_30-70, by laser light scattering. Usually there are no particles larger than 120 nanometers. They have a critical temperature range from at least as low as 40°C. up to about 500°C, i.e., they retain their microemulsion character over this range. This wide range is a singular achievement in medical emulsion technology.
  • microemulsions of my invention are prepared in a certain manner. It is not sufficient to merely add all the ingredients together and thoroughly mix them. Rather, two mixtures, each containing some of the ingredients are separately prepared and then mixed together in a certain procedure.
  • One mixture contains the oil and high molecular weight surfactant.
  • it also contains any other surfactant and other oily ingredients but to achieve a microemulsion as a final product, the surfactant must be mixed with the fatty oil before being mixed with the water. If mixed with the water, the final emulsion is cloudy, has larger particle size and is not as stable. Accordingly the high molecular weight surfactant and the oil are heated to, say, 50°C. to dissolve the surfactant in the oil.
  • the aqueous and oil phases are then mixed together to form a coarse emulsion.
  • the emulsion is referred to as coarse in that it is the kind of emulsion one gets by hand shaking of two immiscible liquids, but it has relatively low stability and either a large average particle size and/or a wide particle size distribution. It is often milky and often has a significant number of particles above one micron.
  • This emulsion is then brought to or heated at above the phase inversion temperature. This is the temperature at which the emulsion, albeit coarse, breaks into two distinct liquid phases. This temperature varies for different compositions but is usually 25-150"C, preferably 65-120°C.
  • Time is also a factor as the "breaking" will often still occur at a lower temperature if a longer time is provided.
  • the time required for the emulsion to break, once it is above the PIT varies but is usually only a matter of several minutes, such as 2-10 minutes, almost always within 3-60 minutes.
  • the difference between the coarse emulsion and the "broken" two-phase system is very striking and readily visible.
  • the oil and aqueous phases can be initially mixed at, say, 95°C, for an 85°C. PIT, and then held at 95°C. until the coarse emulsion breaks.
  • the emulsion Once the emulsion has broken, it is then cooled with gentle mixing or shaking to room temperature (25°C). At about 40-60°C. the microemulsion forms, as is generally evidenced by the appearance of a translucent, shiny blue-yellow single phase.
  • the process of the invention is still applicable, but the formation of the microemulsion will be at a lower temperature. Thus if the coarse emulsion is formed at room temperature and then breaks at 35°C, then the microemulsion may not form until 5-10°C.
  • the aqueous phase can also contain water-soluble excipients such as sugars, mineral salts, flavoring agents, preservatives, etc. These can be added to the aqueous phase in its initial preparation or to the finished emulsion.
  • a principal utility of my emulsions is as a lipophilic or amphipathic drug carrier.
  • the drugs are included in the oil phase, although there is also some distribution or partition, usually not more than 25%, preferably not more than 5%, of the drug between the oil and water phases.
  • the drugs I usually use are either sufficiently lipophilic inherently, or they are made so by adjustments in emulsion pH, but the subsequent examples show that they do not have to be lipophilic. Examples of lipophilic drugs which can be used are described in European Patent 0211258.
  • narcotic analgesics and narcotic antagonists include general anesthetics, local anesthetics, hypnotics, sedatives and anxiolytics, antidepressants, anticonvulsants, narcotic analgesics and narcotic antagonists, nonsteroidal antiinflammatory drugs, anticholinesterases, sympathomimetics and parasympathomimetics, ganglionic stimulating and blocking agents, neuromuscular blocking agents, antimuscarinic agents, adrenergic blocking agents, autacoids and autacoid antagonists, digitalis and digitalis congeners, diuretics and saliuretics, antibiotics and antimicrobials, antineoplastics, immunosuppressants and immunomodulators, hemoglobin and hemoglobin derivatives and polymers, hormones and hormone antagonists, and fat-soluble vitamins, and combinations thereof. Specific drugs within these groups are specifically identified in the aforementioned patent which is incorporated herein by reference.
  • the drugs can be added to the finished emulsion or to the oil phase in its preparation. Preferably, they are added to the furnished emulsion if the drugs are not resistant to the heat sometimes used in sterilizing the emulsion.
  • emulsions of my invention can be sterilized by conventional autoclaving which usually involves heating at about 120°C. Alternatively, they can be sterilized by microfiltration. When heat sterilized, the emulsion will invariably break into two phases, but the single phase microemulsion will return at about 40-60°C. on gentle shaking.
  • Autoclaving for sterilization purposes is preferably done before any drugs are included in the emulsion for the heat resistance considerations mentioned above. If sterilized by filtration, thermal decomposition of the drug is obviously not a problem.
  • Example 2 The procedure is the same as in Example 1 except that the oil phase is 24% and the Ethiodol:Cremophor ratio is 1.5:1. The results are the same in that a microemulsion forms but the particle size is somewhat larger because of the lesser amount of surfactant.
  • EXAMPLE 4 3% (w/v) Ibupro en, 7.5% Captex 200 (C 8 -C 10 fatty acid diester of propylene glycol) and 7.2% Cremophor EL (same as Example 1) are mixed together with heating to dissolve the Ibuprofen in the oil.
  • the aqueous phase is added and mixed to form a crude emulsion.
  • the entire mixture is heated to 90-95°C. to cause phase separation, and is then cooled with mixing to room temperature which causes the microemulsion to form with a particle size of 65 nm.
  • the addition of sucrose to the aqueous phase (up to 20 w/v %) causes the microemulsion particle size to be even smaller.
  • EXAMPLE 5 .041 g. of insulin is dispersed in a 1:1 mixture of coconut oil and polyoxyethylene sorbitan hexaoleate. This dispersing is by homogenization because insulin is not soluble in the oil (nor in the aqueous phase at high pH) .
  • the oil phase is 5%.
  • the aqueous phase (PBS) is added at room temperature and mixed to form a coarse emulsion. This emulsion is heated to 90-95°C. until two distinct phases are seen, then is gently mixed while cooling to room temperature. A microemulsion forms which has a particle size of 35 nanometers. After several days the insulin starts to slowly come out of the oil phase which is not unexpected.
  • EXAMPLE 6 .006 g. Piroxicam (another antiinflammatory drug) is dissolved in .39 ml. Cremophor EL (Example 1), .27 ml. triacetin and .12 ml. Captex 200 (Example 1).
  • the triacetin acetic acid ester of glycerol helps solubilize the drug in the oil. Dissolution is by heating at 95°C. until the white drug powder dissolved in the oil-surfactant system leaving a clear yellow solution.
  • the aqueous phase 2.34 ml. citric acid buffer (pH 2.3) at room temperature, was added to the oil phase which was still- in the oil bath.
  • the emulsion vial was then removed from the bath and cooled to room temperature with gentle mixing. When it first becomes transparent, at 40-50°C., it is immersed in a room temperature water bath to accelerate cooling.
  • the particle size of the finished emulsion is about 25 nm.
  • EXAMPLE 7 This Example is the preparation of a microemulsion of 5.0% lauric oil with 3.5% polyoxyethylene 50 sorbitol hexaoleate as the main surfactant and 1.0% polyoxyethylene 20 sorbitan monolaurate and 0.55 w/v% egg yolk phospholipid (EYP) as secondary surfactants.
  • the oil phase also contained 0.005 w/v% potassium oleate as an anticoalescing agent.
  • the aqueous phase was phosphate buffered saline solution (10 mmoles/1 P0 4 , 300 mosmoles) .
  • the aqueous phase is heated to 85°C. All other ingredients were mixed together and heated to 85 "C. Heating is in a water bath.
  • the two portions were then mixed together and held 85°C. for a few minutes until the crude emulsion broke and were then allowed to cool to room temperature with gentle shaking. At about 60°C. in the cooling cycle the microemulsion forms. It is a transparent single phase with a shiny blue-yellow cast. It has a stability range of at least 4-50°C. The particle size is 30 nanometers which is still the same after ten months storage.
  • EXAMPLE 8 The procedure is the same as in Example 7 except that the aqueous phase is 0.9 wt % NaCl solution. The pH of the finished microemulsion is adjusted from 2 to 10 with NaOH and HCl. There was no damage to the emulsion.

Abstract

Microémulsions d'huiles grasses dans de l'eau préparées par chauffage d'une émulsion brute de ces ingrédients au-dessus de la température d'inversion de phase, puis par refroidissement à la température ambiante. Ces émulsions sont utiles pour l'administration de médicaments.
PCT/US1991/003991 1990-06-08 1991-06-06 Procede servant a preparer des microemulsions WO1991018669A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP3514039A JPH06511419A (ja) 1990-06-08 1991-06-06 ミクロエマルジョンを製造する方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53502590A 1990-06-08 1990-06-08
US535,025 1990-06-08

Publications (1)

Publication Number Publication Date
WO1991018669A1 true WO1991018669A1 (fr) 1991-12-12

Family

ID=24132557

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1991/003991 WO1991018669A1 (fr) 1990-06-08 1991-06-06 Procede servant a preparer des microemulsions

Country Status (4)

Country Link
EP (1) EP0532703A4 (fr)
JP (1) JPH06511419A (fr)
CA (1) CA2083711A1 (fr)
WO (1) WO1991018669A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2703926A1 (fr) * 1993-04-13 1994-10-21 Shiseido International France Micro-émulsion stable procurant une pulvérisation à contact sec, procédé de préparation et dispositif de mise en Óoeuvre.
EP0666752A1 (fr) * 1992-10-16 1995-08-16 Smithkline Beecham Corporation Microemulsions therapeutiques
EP0671937A1 (fr) * 1992-10-16 1995-09-20 Smithkline Beecham Corporation Compositions pour emulsions pharmaceutiques
EP0671929A1 (fr) * 1992-10-16 1995-09-20 Smithkline Beecham Corporation Compositions
EP0696452A1 (fr) * 1994-08-08 1996-02-14 Laboratorios Cusi, S.A. Nanoémulsion du type huile dans eau, utilisable comme véhicule ophthalmique et procédé pour sa préparation
EP1135150A1 (fr) * 1998-12-11 2001-09-26 Pharmasolutions, Inc. Compositions auto-emulsifiantes pour medicaments peu solubles dans l'eau
WO2003097010A1 (fr) * 2002-05-15 2003-11-27 Johannes Wohlrab Formulation pharmaceutique sous forme colloidale pour application topique, servant a la therapie et a la prophylaxie d'etats douloureux et prurigineux
US20120027825A1 (en) * 2008-12-12 2012-02-02 Inst Nat De La Sante Et De La Recher. Med (Inserm) Method of preparing lipid nanoparticles

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4847072A (en) * 1987-10-22 1989-07-11 The Procter & Gamble Company Photoprotection compositions comprising tocopherol sorbate
US4857335A (en) * 1987-03-27 1989-08-15 Lim Technology Laboratories, Inc. Liquid controlled release formulations and method of producing same via multiple emulsion process

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6042322A (ja) * 1983-08-19 1985-03-06 Nippon Kayaku Co Ltd 新規な乳化製剤
DE3819193A1 (de) * 1988-06-06 1989-12-07 Henkel Kgaa Verfahren zur herstellung stabiler, niedrigviskoser oel-in-wasser-emulsionen polarer oelkomponenten

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4857335A (en) * 1987-03-27 1989-08-15 Lim Technology Laboratories, Inc. Liquid controlled release formulations and method of producing same via multiple emulsion process
US4847072A (en) * 1987-10-22 1989-07-11 The Procter & Gamble Company Photoprotection compositions comprising tocopherol sorbate

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP0532703A4 *

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0671937A4 (fr) * 1992-10-16 1996-09-18 Smithkline Beecham Corp Compositions pour emulsions pharmaceutiques.
EP0671937A1 (fr) * 1992-10-16 1995-09-20 Smithkline Beecham Corporation Compositions pour emulsions pharmaceutiques
EP0671929A1 (fr) * 1992-10-16 1995-09-20 Smithkline Beecham Corporation Compositions
EP0671929A4 (fr) * 1992-10-16 1996-09-25 Smithkline Beecham Corp Compositions.
EP0666752A4 (fr) * 1992-10-16 1996-09-11 Smithkline Beecham Corp Microemulsions therapeutiques.
EP0666752A1 (fr) * 1992-10-16 1995-08-16 Smithkline Beecham Corporation Microemulsions therapeutiques
FR2703926A1 (fr) * 1993-04-13 1994-10-21 Shiseido International France Micro-émulsion stable procurant une pulvérisation à contact sec, procédé de préparation et dispositif de mise en Óoeuvre.
EP0696452A1 (fr) * 1994-08-08 1996-02-14 Laboratorios Cusi, S.A. Nanoémulsion du type huile dans eau, utilisable comme véhicule ophthalmique et procédé pour sa préparation
US5698219A (en) * 1994-08-08 1997-12-16 Laboratorios Cusi, S.A. Nanoemulsion of the oil water type, useful as an ophthalmic vehicle and process for the preparation thereof
EP1135150A1 (fr) * 1998-12-11 2001-09-26 Pharmasolutions, Inc. Compositions auto-emulsifiantes pour medicaments peu solubles dans l'eau
EP1135150A4 (fr) * 1998-12-11 2006-05-17 Pharmasolutions Inc Compositions auto-emulsifiantes pour medicaments peu solubles dans l'eau
WO2003097010A1 (fr) * 2002-05-15 2003-11-27 Johannes Wohlrab Formulation pharmaceutique sous forme colloidale pour application topique, servant a la therapie et a la prophylaxie d'etats douloureux et prurigineux
US20120027825A1 (en) * 2008-12-12 2012-02-02 Inst Nat De La Sante Et De La Recher. Med (Inserm) Method of preparing lipid nanoparticles
US9302241B2 (en) * 2008-12-12 2016-04-05 Universite D'angers Method of preparing lipid nanoparticles

Also Published As

Publication number Publication date
EP0532703A1 (fr) 1993-03-24
EP0532703A4 (en) 1993-05-26
CA2083711A1 (fr) 1991-12-09
JPH06511419A (ja) 1994-12-22

Similar Documents

Publication Publication Date Title
Collins-Gold et al. Parenteral emulsions for drug delivery
JP5165249B2 (ja) 麻酔用高濃度プロポフォールのマイクロエマルジョンの調製
KR100861820B1 (ko) 미생물 특성이 증진된 프로포폴 제제
US4252793A (en) Injectable lecithin preparation
WO1997030695A1 (fr) Compositions d'apport medicamenteux convenant a l'injection intraveineuse
KR19980701770A (ko) 미셀 미소입자
JPH11500737A (ja) プロポフォールとエデテートとを含有する水中油滴エマルジョン
EP1539122A2 (fr) Compositions pharmaceutiques de 2,6-diisopropylphenol aqueux
CZ300790B6 (cs) Vodný prípravek z propofolu
WO1994014415A1 (fr) Emulsions d'hydrocarbure fluore
WO1991018669A1 (fr) Procede servant a preparer des microemulsions
EP1906921B1 (fr) Microemulsion pharmaceutique aqueuse et transparente comprenant du propofol, et son procede de preparation
JP2003525892A (ja) 脂質担体
JPH08508016A (ja) キットの形の薬剤学的組成物
JPS6014933A (ja) 水中油型エマルシヨンの製造方法
JP2002541087A (ja) 防腐添加剤を含有するプロポフォール組成物
JPS60260511A (ja) 安定なエマルジヨン製剤
MXPA06009197A (en) A microemulsion preparation of high concentration propofol for anesthetic uses

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 2083711

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1991915009

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1991915009

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1991915009

Country of ref document: EP